Immediate Impact
60 standout
Citing Papers
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Works of Erika Bågeman being referenced
A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody.
2020
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Erika Bågeman | 127 | 63 | 71 | 79 | 14 | 280 | |
| H Soliman | 66 | 20 | 47 | 13 | 18 | 317 | |
| Ashok Subramanian | 74 | 56 | 8 | 15 | 19 | 313 | |
| Meggan Valrance | 68 | 131 | 13 | 14 | 10 | 335 | |
| Caterina Chiodino | 72 | 25 | 27 | 9 | 13 | 307 | |
| Samira El Bouazzaoui | 152 | 9 | 6 | 17 | 17 | 304 | |
| Xiao-Jian Qin | 60 | 18 | 9 | 20 | 18 | 330 | |
| M Salhab | 100 | 83 | 30 | 2 | 18 | 314 | |
| Laurent Klapholz | 67 | 14 | 16 | 4 | 13 | 236 | |
| Saranya Ravi | 70 | 72 | 22 | 2 | 11 | 280 | |
| Jianfeng Zhang | 33 | 63 | 11 | 6 | 13 | 321 |
All Works
Loading papers...